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1. INTRODUCTION 
 
1.1. Rare diseases 
 
Rare diseases affect only a small percentage of the population. Their 
incidence is 1:2000 or less as defined by the European Union. Rare diseases affect 
nationwide only a few patients, but altogether they affect a significant portion of the 
population since their thousands of different types are known. In general, these 
disorders are less known than the common ones. They occur rarely in the everyday 
practice of the medical practitioners and less attention is paid for the research of 
these diseases (Kelsall et al., 2013). However, rare diseases can vary greatly. They 
can cause mild, severe or very severe symptoms and can be associated with 
phenotypic diversity like common diseases. Their symptoms can impair the life 
quality of the patient significantly and they can also result in stigmatization and 
difficulties in socialization (Kelsall et al., 2013).  
Regarding common diseases, several predisposing factors might play a role in 
their development, such as environmental, life style and genetic factors. In contrast to 
common diseases, rare diseases are usually monogenic, meaning that one defined 
genetic alteration, one gene defect and consequently failure of one protein can be 
critical and can lead to the development of the disease. According to our current 
knowledge, the number of different human monogenic disorders is estimated to be 
more than 10000 (Orphanet Database, www.orpha.net). According to the data of the 
WHO, the global prevalence of monogenic diseases is approximately 10:1000 at 
birth (Kelsall et al., 2013). These diseases usually follow the rules of Mendelian 
inheritance and they are inherited in autosomal or sex chromosome-linked and 
dominant or recessive mode. 
In my thesis, I have summarized the results of my genetic investigations in 
rare, very stigmatizing monogenic diseases: LEOPARD syndrome and the clinical 
variants of the cylindromatosis gene (CYLD) mutation-caused disease spectrum such 
as multiple familial trichoepithelioma type 1 (MFT1), familial cylindromatosis (FC) 
and Brooke-Spiegler syndrome (BSS).  
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1.2. LEOPARD syndrome 
 
1.2.1. Clinical symptoms 
 
LEOPARD syndrome (LS, MIM 151100) is a rare monogenic disorder 
belonging to the family of neuro-cardiofacio-cutaneous syndromes (Spatola et al., 
2015). It is inherited as an autosomal dominant trait with full penetrance and variable 
expressivity (Digilio et al., 2002; Legius et al., 2002). The major features of LS 
include multiple lentigines, electrocardiographic conduction abnormalities, ocular 
hypertelorism, pulmonary stenosis, abnormal genitalia, retardation of growth and 
sensorineural deafness, this is why the syndrome is referred with the LEOPARD 
acronym (Digilio et al., 2006; Legius et al., 2002). In the literature there are some 
other names of the disease as multiple lentigines syndrome, Moynahan syndrome or 
progressive cardiomyopathic lentiginosis. The symptoms were first described by 
Zeisler and Becker in 1936, and then the acronym was created by Gorlin in 1969. 
 
1.2.2. Genetic background 
 
LS is the consequence of mutations located in the protein-tyrosine 
phosphatase nonreceptor-type 11 (PTPN11) gene. The locus of the gene responsible 
for LS is localized at 12q24. The PTPN11 gene contains 16 exons, the last one is 
untranslated, and 15 introns (Figure 1). The gene encodes a cytoplasmic protein 
tyrosine phosphatase (SHP-2), which regulates intracellular signaling and controls 
several distinct developmental processes (Sarkozy et al., 2008; Tartaglia et al., 
2001). 
Figure 1. Schematic drawing of the protein-tyrosine phosphatase nonreceptor-type 
11 (PTPN11) gene (Ensembl Genome Browser). The horizontal line illustrates the 
gene, the vertical lines represent the location and the size of exons. 
 
So far 12 mutations in the PTPN11 gene have been found to cause LS. In 
about 85% of the cases a heterozygous missense mutation is detected in the exon 7, 
12 or 13. Among the so far identified missense mutations, there are two 
5’ 3’ 
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(p.Tyr279Cys and p.Thr468Met), which account for about 65% of all LS cases 
worldwide (Kalev et al., 2010; Limongelli et al., 2008). 
 
1.3. The CYLD mutation-caused disease spectrum 
 
1.3.1. Multiple familial trichoepithelioma type 1 
 
Multiple familial trichoepithelioma type 1 (MFT1; MIM 601606) is an 
autosomal dominant condition characterized by numerous firm skin-colored papules 
that are trichoepitheliomas (follicular tumors). The tumors grow slowly in size and 
number throughout life, often producing significant cosmetic disfigurement. 
Trichoepitheliomas are small benign skin-colored tumors and are typically present at 
the center of the face, mostly around the nose, periorbitally and in the nasolabial 
folds (Uede et al., 2004). Histologically, trichoepitheliomas are characterized by 
basaloid cells with peripheral palisades that are arranged in nests or cribriform 
patterns surrounded by dense stroma and fibroblasts (Alsaad et al., 2007). 
 
1.3.2. Familial cylindromatosis 
 
Familial cylindromatosis (FC, MIM 132700) is also an autosomal dominantly 
inherited disorder. Patients with FC have cylindromas, which are slowly growing 
benign tumors that are usually located on the scalp and face. Typically, they appear 
as multiple turban-like protrusions on the scalp, which are also referred as turban 
tumors (Uede et al., 2004). Cylindromas are histologically characterized by dermal 
nodules of epithelial cells: large cells with abundant cytoplasm occur at the center of 
the tumors, whereas small basaloid cells occur at the periphery. The cells are lined by 
membrane-like basement material and arranged in a “jigsaw puzzle” pattern (Lian 
and Cockerell, 2005). Cylindromas express hair keratins (Massoumi et al., 2006). 
 
1.3.3. Brooke-Spiegler syndrome 
 
 Brooke-Spiegler syndrome (BSS, MIM 605041) is also a rare monogenic skin 
disease characterized by the development of a wide variety of benign skin appendage 
tumors, such as trichoepitheliomas, cylindromas and/or spiradenomas (Brooke, 1892; 
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Spiegler, 1899). The first symptoms of BSS are small skin-colored papules, which 
occur in childhood and adolescence (Evans, 1954; Sima et al., 2010). These tumors 
grow slowly in size and continue appear throughout the lifetime of the patient (Blake 
and Toro, 2009). Expression of the papules exhibits wide variation among and within 
affected families (Poblete et al., 2002). Spiradenomas are purple benign nodular 
tumors, which are usually located on the trunk or limbs (Uede et al., 2004). 
Histologically, spiradenomas are composed of large tumor nests comprising two 
types of epithelial cells (Obaidat et al., 2007). Large light-colored cells with 
abundant cytoplasm at the center of the nests are surrounded by small darker cells at 
the periphery (Obaidat et al., 2007; Michal et al., 1999). Spiradenomas rarely 
become malignant but can transform into spiradenocarcinomas (Cooper et al., 1985; 
Engel et al., 1991; Chou et al., 2004). Hybrid tumors can also occur, such as 
spiradenocylindromas, which exhibit the characteristics of both cylindromas and 
spiradenomas (Kazakov et al., 2005; Kazakov et al., 2008; Pizinger and Michal, 
2000). 
 
1.3.4. Genetic background 
 
MFT1, FC and BSS have been independently mapped to chromosome 16q12-
q13 by several groups (Biggs et al., 1995; Biggs et al., 1996; Bignell et al., 2000). 
First, FC was mapped to this region in 1995 (Biggs et al., 1995), and its candidate 
gene, the CYLD gene, was identified in 2000 (Bignell et al., 2000). Later BSS was 
mapped to the same region in 2000 (Fenske et al., 2000). In the mapped region, the 
same causative gene was identified in 2002 (Gutierrez et al., 2002). Regarding 
MFT1, the same causative gene was identified in 2003 (Hu et al., 2003). In the 
mapped region, the cylindromatosis (CYLD) gene [NM_015247] was identified as 
the causative gene responsible for the development of these three diseases (Bignell et 
al., 2000). The gene spans 56 kb and contains 20 exons, the first 3 of which are 
untranslated, and 19 introns (Figure 2).  
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Figure 2. Schematic drawing of the cylindromatosis (CYLD) gene (Ensembl Genome 
Browser). The horizontal line illustrates the gene, the vertical lines represent the 
location and the size of exons. 
 
The tumor suppressing CYLD gene encodes an enzyme with deubiquitinase 
activity. The CYLD enzyme post-translationally modifies its target proteins by 
removing Lys63-linked ubiquitin chains (Kovalenko et al., 2003). The protein 
interacts with several members of the NF-ĸB signaling pathway, including TNF-
receptor-associated factor proteins (TRAF2, TRAF6 and TRAF7) and the NEMO 
protein as a negative regulator of the NF-kB signaling pathway (Haglund and Dikic, 
2005). CYLD is involved in the regulation of several biological processes, such as 
cell proliferation and inflammation (Gao et al., 2008) (Figure 3).  
 
 
Figure 3. Model of the effect of CYLD deubiquitinase enzime on the activation of 
NF-κB signaling pathway. CYLD protein has a role in the regulation of NF-κB 
signaling pathway throuhg the deubiquitination of NEMO protein.  
 
To date, a total of 95 mutations have been reported for the CYLD gene. In 
2000, the first 21 mutations of the CYLD gene were identified in the affected 
members of 21 families with FC (Bignell et al., 2000). Since 2000, several reports 
have described mutations in the CYLD gene in different cases from around the world 
(Blake and Toro, 2009). In addition to BSS and FC, mutations of the CYLD gene 
5’ 3’ 
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have also been reported in patients with MFT1 (Hu et al., 2003). BSS, FC and MFT1 
show overlapping phenotypic features: some BSS patients develop multiple skin 
appendage tumors including cylindromas, trichoepitheliomas, and spiradenomas, 
whereas patients with FC develop only cylindromas, and patients with MFT1 
develop only trichoepitheliomas (Brooke, 1892; Spiegler, 1899; Ancell, 1842; 
Fordyce, 1892; Zhang et al., 2004) (Table 1).  
 
 Familial 
cylindromatosis 
(FC)  
Brooke-Spiegler 
syndrome (BSS) 
Multiple familial 
trichoepithelioma               
type 1 (MFT1)  
OMIM 
ID  
132700  605041  601606  
Clinical 
symptoms  
Predominantly 
cylindromas  
Cylindromas, 
trichoepitheliomas, 
spiradenomas  
Predominantly 
trichoepitheliomas 
CYLD 
mutations  
Any type of 
mutation  
Any type of mutation  
Any type of mutation, 
mostly missense  
Table 1. Phenotypes caused by mutations of CYLD gene. 
 
BSS, FC and MFT1 were originally described as distinct clinical entities, but 
due to their overlapping clinical symptoms and their manifestation within the same 
families, they are now considered as clinical variants that represent a phenotypic 
spectrum of a single entity (Lee et al., 2005; Welch et al., 1968; Young et al., 2006; 
Oranje et al., 2008).  
 
1.4. Aims 
 
In my thesis, the primary aim was to summarize the results of the genetic and 
functional investigations in stigmatizing rare monogenic disorders: LS and the 
clinical variants of the CYLD mutation-caused disease spectrum such as BSS, FC and 
MFT1. 
Concerning LS, the aim was to identify the underlying causative genetic 
abnormality in a 51-year-old Hungarian male patient. Besides, the genetic 
investigations aiming to identify the disease-causing mutation, it was also among my 
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goals to compare this variant with the reported ones in the literature in order to define 
genotype-phenotype correlations and Hungarian population specific mutations.  
Regarding CYLD mutation-caused disease spectrum, my aim was to 
investigate families and sporadic cases affected by BSS, FC or MFT1 in order to 
identify the underlying genetic abnormalities. I have also aimed to perform further 
genetic investigations including haplotype analysis to demonstrate whether different 
cases and families affected by different clinical variants of the CYLD mutation-
caused disease spectrum carrying the same CYLD mutation are the consequence of 
the same founder event or independent mutational events. In case of novel mutations, 
I have also aimed to perform functional investigations to prove their ability to impair 
the function of the encoded CYLD enzyme. Besides these investigations, my further 
goals were to describe genotype-phenotype correlations and population specific 
mutation database. 
Since rare diseases can affect only a few families in Hungary, it was also 
among my goals to build international strong co-operations with the researchers and 
clinicians working in this field. In my thesis, I have summarized my investigations, 
which have been performed on not only Hungarian, but Spanish, Dutch and Austrian 
patients carrying the same CYLD mutation.  
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2. PATIENTS AND METHODS 
 
2.1. Patients 
 
2.1.1. Hungarian pedigree affected by LEOPARD syndrome 
 
A 51-year-old Hungarian male patient was admitted to the cardiology unit of 
the Orosháza Hospital (Orosháza, Hungary) with dizziness and palpitation. On 
investigation, facial anomalies including ocular hypertelorism, palpebral ptosis, 
dysmorphic ear, slight mandibular prognathism (Figure 4a) and pigmentation 
abnormalities such as multiple lentigines (Figure 4b) and café-au-lait spots (Figure 
4c) were also observed. Cardiology investigations revealed third degree 
atrioventricular block (Figure 4d). The patient is deaf and dumb since he was born 
and mild growth as well as mental retardations were also present. Urological 
investigation revealed mild genital abnormalities such as atrophic testes. These 
clinical symptoms suggested LS. 
 
 
Figure 4. The clinical symptoms of the patient. Facial dysmorphims including ocular 
hypertelorism, palpebral ptosis, slight mandibular prognathism and dysmorphic ears 
(a). Pigmentational abnormalitieson the skin: multiple lentigines (b) and café-au-lait 
spots (c). On electrocardiography a third degree antrioventricular block was present 
d). (Nemes and Farkas et al., 2015) 
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The patient was born out of wedlock, however the family members of his 
father and his mother were available for the clinical and genetic investigations. They 
were all clinically unaffected individuals (Figure 5).  
 
 
Figure 5. Hungarian pedigree affected by LS. (Nemes and Farkas et al., 2015) 
 
2.1.2. Spanish pedigree affected by multiple familial trichoepithelioma type 1 
 
 The Spanish MFT1 pedigree of Hispanic origin was identified in the Levant 
region of Valencia, Spain. The 62-year-old father exhibited skin lesions that 
developed progressively on the central area of the face since the age of 14. Multiple 
skin-colored papules were present in both nasolabial folds (Figure 6a), on the 
forehead, above the eyebrows and, to a lesser extent, on the ears, on the back of the 
head and on the back. Histological examination revealed the diagnosis of 
trichoepithelioma (Figure 6b). The patient has been followed for 24 years, during 
which time the lesions have increased in number and size.  
The patient’s only child, a 33-year-old daughter, has lesions similar to those 
of her father but are fewer in number (Figure 6c). The lesions first appeared in both 
nasolabial folds and, over time, began to appear on her forehead, temples, ears and 
scalp.  
No other clinically affected member has been identified in this pedigree 
(Figure 6d). 
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Figure 6. Skin symptoms (a,c), histology findings (b) and pedigree (d) of a Spanish 
family with multiple familial trichoepithelioma type 1. (Farkas et al., 2016) 
 
2.1.3. Dutch patients affected by familial cylindromatosis 
 
The investigated Dutch patients were previously reported by Van den 
Ouweland et al. Based on the development of cylindromas, these patients were 
diagnosed with FC. Their detailed clinical description is present in the report of Van 
den Ouweland et al. (Van den Ouweland et al., 2011). 
 
2.1.4. Austrian patient affected by Brooke-Spiegler syndrome 
 
 The investigated Austrian patient was previously reported by Grossmann et 
al. Based on the development of different skin appendage tumors, the diagnosis of 
BSS was established. The detailed clinical description of the symptoms is available 
in the study of Grossmann et al. (Grossmann et al., 2013). 
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2.1.5. Hungarian pedigree from Szekszárd affected by Brooke-Spiegler 
syndrome 
 
A Hungarian pedigree, located in Hungary close to Szekszárd, has 
Bukovinian (Romania) origin affected by BSS was investigated. 21 affected family 
members were in the seven-generation family (Figure 7).  
 
 
Figure 7. The investigated Hungarian BSS pedigree contains 21 affected family 
members spanning seven-generations. (Nagy et al., 2013) 
 
The affected individuals have serious skin appendage tumors (Figure 8). 
Some of them have cylindromas on the scalp and trichoepitheliomas on the face. The 
tumors appeared in early life as small nodule and progressively enlarged and 
developed also on the back and on the extremities of the patients.  
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Figure 8. Clinical pictures of the severe hairy scalp symptoms of the affected 
individuals are represented from the 2
nd
 (a), 3
rd
 (b) and 4
th
 (c) generations. (Nagy et 
al., 2013) 
 
2.1.6. Anglo-Saxon pedigree affected by Brooke-Spiegler syndrome 
 
The Anglo-Saxon BSS pedigree from the north of England was also 
investigated. This pedigree contained 8 affected family members spanning five 
generations (Figure 9).  
 
 
Figure 9. The investigated Anglo-Saxon pedigree from the North of England 
contains 8 affected family members spanning five-generations. (Nagy et al., 2013)  
 
The affected individuals had a comparatively milder phenotype, with 
cylindromas and spiradenomas on the scalp and trichoepitheliomas on the face 
(Figure 10).  
 
a 
 
b c 
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Figure 10. Clinical pictures of the affected individuals from the 4
th
 generation shows 
tumors above the ear (a), on the forehead (b) and around the nose (c). (Nagy et al., 
2013) 
 
2.1.7. Hungarian pedigree from Szeged affected by Brooke-Spiegler syndrome 
 
A pedigree from the Southern part of Hungary (Szeged region) affected by 
BSS was investigated. The pedigree has 2 affected and 5 unaffected individuals 
spanning two generations (Figure 11).  
 
 
Figure 11. The investigated Hungarian pedigree has two clinically affected 
individuals. (Nagy et al., 2012) 
 
One of the affected individuals, a 60-year-old male (I-1), has numerous soft, 
hairless, skin-colored papules around his nose, in his ears, on his scalp and on his 
shoulders (Figure 12). Some of the tumors in the head and neck region were 
surgically removed. Routine histological examination of the excised tumors 
a b c 
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suggested the diagnosis of the BSS. His daughter (II-2), a 35-year-old female, 
presented with milder symptoms.  
 
 
Figure 12. Numerous skin-colored, dome-shaped tumors are present on the shoulder 
(a), on the back (b), around the nose (c), in the retroauricular region (d) and in the 
ears (e-f) of patient I-1. (Nagy et al., 2012) 
 
2.2. Methods 
 
2.2.1. DNA isolation 
 
 After pre-test genetic counseling was performed and written informed 
consents were obtained from the enrolled patients and controls according to a 
protocol approved by the Local Ethics Committee in adherence to the Helsinki 
guidelines, blood samples were taken from the patients. Genomic DNA was isolated 
from whole blood samples using a QIAamp DNA Blood Mini Kit (QIAGEN; 
Hilden, Germany). During the isolation, after proteinase K digestion, washings with 
alcohol were done following the instructions. Genomic DNA was dissolved in 100 μl 
distilled water. 
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2.2.2. Polymerase chain reaction (PCR) amplification 
 
 During PCR amplification, 4 μl genomic DNA was used as template. In 
addition, the reaction mix contains 9 μl Dream Taq Green PCR Master Mix 
(Fermentas), 4 μl distilled water, 1,5 μl forward and 1,5 μl reverse primers. The using 
primers sequences obtained from the UCSC Genome Browser 
(www.genome.ucsc.edu) and Primer3 (http://bioinfo.ut.ee/primer3-0.4.0/). A 
MyCycler PCR machine (BioRad) was used following the PCR conditions: 
 
1. step: 95
o
C for 10 min 
2. step: 95
o
C for 30 sec (denaturation) 
3. step: 59
o
C for 30 sec (annealing) 
4. step: 72
o
C for 45 sec (synthesis) 
5. step: 72
o
C for 10 sec  
6. step: 4
oC ∞ 
 
The 2
nd
, 3
rd
 and 4
th
 steps were repeated 40 times. The annealing temperature and the 
number of the cycles were depended on the primers, the synthesis reaction time was 
determined according to the length of the reaction product. 
 
2.2.3. Gel electrophoresis and gel documentation 
 
 The PCR products were checked on 2% agarose gel (SeaKem LE agarose, 
Lonza) using TBE buffer (Lonza) and visualized by 2,5 μl GelRed (Biotium) 
staining. The gel was analyzed by BioRad Molecular Imager® GelDoc™ XR gel 
documentation system with QuantityOne software.  
 
2.2.4. Sequencing 
 
 The sequencing was performed after the suitable purifying of the PCR 
reaction products using Big Dye Terminator v3.1 Cycle sequencing kit (Applied 
Biosystems) with ABI Prism 7000 (Applied Biosystems) sequencing machine. The 
service of the sequencing was offered by Delta Bio 2000 Kft. 
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2.2.5. Haplotype analysis 
 
For the haplotype analysis, common polymorphisms located in the 3’ and 5’ prime 
region of the identified mutation were genotyped using direct sequencing of the 
flanking coding and non-coding regions of the CYLD gene.  
 
2.2.6. Immunoprecipitation 
 
Four-mm punch biopsy samples were collected from patients affected by 
Brooke-Spiegler syndrome (n=2) and from healthy individuals (n=2). After Dispase 
(Grade II, Roche Applied Science) digestion, fibroblasts were isolated and cultured 
using standard methods. After washing with PBS, fibroblasts were suspended in 1 ml 
lysis buffer (Sigma) then samples were homogenized with a pre-chilled 
homogenizer. According to the instructions of the Immunoprecipitation Kit Protein G 
(Roche Applied Science), NEMO protein was immunoprecipitated with anti-human 
NEMO mouse antibody (BD Pharmingen) from fibroblasts of BSS patients and 
healthy donors.  
 
2.2.7. Western blot analysis 
 
Equal amounts of the immunoprecipitated NEMO proteins were run on 10% 
SDS-polyacrylamide gel. The proteins were transferred from the gel to nitrocellulose 
membrane by dry blot system (iBlot Gel Transfer System, Invitrogen). The 
membranes were saturated in TBS containing 3% nonfat dry milk for 2 hours. 
Western blot was performed using anti-human ubiquitin mouse primary antibody 
(Santa Cruz Biotechnology) to detect the ubiquitination of the loaded samples. The 
nitrocellulose membrane was incubated in TBS containing 3% nonfat dry milk 
overnight. After washings, alkaline phosphatase-conjugated
 
rabbit anti-mouse IgG 
(Sigma) was used as secondary antibody and blots were developed by using 5-
bromo-4-chloro-3-indolyl phosphate/nitroblue
 
tetrazolium (Sigma) as substrate. 
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3. RESULTS 
 
3.1. Genetic investigation of the protein-tyrosine phosphatase nonreceptor-type 
11 (PTPN11) gene 
 
The coding regions and the flanking introns of the PTPN11 gene were 
amplified. Primers were used as displayed on the UCSC Genome Browser 
(www.genome.ucsc.edu) (Table 2). 
Primer 5'-3' sequence 
PTPN11-X1-F AGC GGA GCC TGA GCA AG 
PTPN11-X1-R GGA GGC AGG AAA TGA ATG G 
PTPN11-X2-F TGT TGT GGA AAG TAG TGC TGA C 
PTPN11-X2-R ATC CAA GCA TGG TTT TAC CAC 
PTPN11-X3-F AAT CCG ACG TGG AAG ATG AG 
PTPN11-X3-R TCT GAC ACT CAG GGC ACA AG 
PTPN11-X4-F TTG TGT TTA GGA GAG CTG ACT G 
PTPN11-X4-R AAC ATC TTG CCA GAC CCA TT 
PTPN11-X5-F TGG AAT TAC TGG CGT GAG C 
PTPN11-X5-R TTG AAG CTG CAA TGG GTA CA 
PTPN11-X6-F ACA CGG TGA AAC GAT TTG AA 
PTPN11-X6-R TCA GTT TCA AGT CTC TCA GGT CC 
PTPN11-X7-F AGA AGT AAT GCT GAT CCA GGC 
PTPN11-X7-R CCG ATG TGC TAA CAA GAG CA 
PTPN11-X8/9-F ACT TGG ACT AGG CTG GGG AG 
PTPN11-X8/9-R TCC TAA ACA TGG CCA ATC TG 
PTPN11-X10-F TGC TTG TTT AGG CTT TTA TTT CAG 
PTPN11-X10-R GGC AAG ACC CTG AAT TCC TAC 
PTPN11-X11-F CGG GTG ATT CCT CAA CCT C 
PTPN11-X11-R GCA GTT GCT CTA TGC CTC AA 
PTPN11-X12-F AAT GGC TTG GTT TTG AGT CTG 
PTPN11-X12-R TTC AAC CTC TCT TCC CCA GA 
PTPN11-X13-F AAC AAC TTC ATC CTG GCT CTG 
PTPN11-X13-R AAG GAG AGC GTA TCC AAG AGG 
PTPN11-X14-F CCT CAC ATG TGC ACT CTT CC 
PTPN11-X14-R CCA GTG AAA GGC ATG TGC TA 
PTPN11-X15-F TCT GGT GCC CAA AGA ATG TAG 
PTPN11-X15-R AAC ATT CCC AAA TTG CTT GC 
Table 2. The list of primers used for the genetic investigations. 
 
 The results of PCR were checked by agarose gel electrophoresis 
(Figure 13) and DNA sequencing was performed.  
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Figure 13. Examination of the samples on agarose gel after the amplification. 
 
Direct sequencing of the coding regions and the flanking introns of the 
PTPN11 gene revealed a heterozygous missense mutation (c.836A/G; p.Tyr279Cys) 
in the seventh exon (Figure 14a). The clinically affected patient carried the mutation 
in heterozygous form, while the unrelated healthy controls (n=30) carried the wild 
type sequence (Figure 14b).  
 
 
Figure 14. Direct sequencing revealed a heterozygous missense mutation (c.836A/G; 
p.Tyr279Cys) in the seventh exon of the PTPN11 gene. The patient carried the 
mutation in heterozygous form (a), while the unrelated controls carried the wild type 
sequence (b). (Nemes and Farkas et al., 2015) 
 
The investigated Hungarian LS patient carries one of the most common 
missense mutation of the PTPN11 gene. Functional studies demonstrated that the 
p.Tyr279Cys heterozygous missense mutation of the PTPN11 gene perturbs the 
switching of the SHP-2 protein between its catalytically inactive and active 
conformation and engenders loss of SHP-2 catalytic activity (Tartaglia et al., 2006).  
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3.2. Genetic, haplotype and functional investigation of the cylindromatosis 
(CYLD) gen 
 
3.2.1. Genetic investigation of the Spanish pedigree 
 
Since the 99% of the identified mutation of the CYLD gene are located in 
exons 9-20, these coding regions and the flanking introns of the CYLD gene were 
amplified. Primers were used as displayed on the UCSC Genome Browser 
(www.genome.ucsc.edu) (Table 3). 
 
Primer  5'-3' sequence 
CYLD-X9-F TCC TAT CTT GAC TTT TGG GCT G 
CYLD-X9-R TCT GAT GAG TTA GAA AGA AAG GAT CA 
CYLD-X10-F AGG TCA GGT GGG CAG TTG 
CYLD-X10-R GCG AAA TCT GCA CAA AAC C 
CYLD-X11-F CAG GTC TTA GAA ACC TTA GTT CTT TG 
CYLD-X11-R TAT TAA AAC ACT GTC ACC ATC ACC 
CYLD-X12-F TTA ACC AAA GCC TAC TTT CCA C 
CYLD-X12-R GTG TCC CTG CCT CAT GG 
CYLD-X13-F TCT TGA AAA ATA TGT TTA CAG CAT GA 
CYLD-X13-R CCA TAA GAA CTA ATT TTC ACC CAT C 
CYLD-X14-F CCA CTG CAC ACT CCA GCC 
CYLD-X14-R AAC TAC ACA GAC ACA CAT TTC AGC 
CYLD-X15-F TGA TTT AAA AAT TTT GCC TGT GA 
CYLD-X15-R TGC ATG ATA TTC CCC TAG CC 
CYLD-X16-F TGT TCT CAA ATA CTG CTG GGA C 
CYLD-X16-R TGT GTT TCA AAC TTT TCT CAG C 
CYLD-X17-F TTG ACA GCC ATG ACT ATT TTG G 
CYLD-X17-R GGG AAA TAC TGT GTC CAG TTA GAG 
CYLD-X18-F TGA AGC CAT GAA CAT TGT CCT 
CYLD-X18-R AAC GAG CAT TGT GTT TTC AAC 
CYLD-X19-F TCA GGC TGG TCT TGA ACT CC 
CYLD-X19-R GCG ATC CCA CTA CAA ACT GTC 
CYLD-X20-F TGG CAA AAG GGT TTA GAA CTT G 
CYLD-X20-R ACG TGA ACA GAA CTG CCA GC 
Table 3. The list of primers used for the genetic investigations. 
 
The results of PCR were checked by agarose gel electrophoresis (Figure 15) 
and DNA sequencing was performed.  
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Figure 15. Examination of the samples on agarose gel after the amplification 
 
Direct sequencing of the coding regions and the flanking introns of the CYLD 
gene from the investigated Spanish patients revealed a previously described nonsense 
mutation in exon 17 (c.2272C/T, p.R758X, CM001116, rs121908388). Both patients 
carried the mutation in heterozygous form (Figure 16a), whereas the unaffected 
family members and the unrelated controls carried the wild-type sequence (Figure 
16b).  
 
 
Figure 16. Direct sequencing of the CYLD gene. The affected family members 
carried the nonsense mutation (c.2272C/T, p.R758X) in heterozygous form (a). The 
unaffected family members carried the wild-type sequence (b). (Farkas et al., 2016) 
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3.2.2. Haplotype analysis of the Spanish pedigree, the Dutch and the Austrian 
patients 
 
Previously reported Dutch and Austrian cases carrying the same mutation - 
that was identified in the Spanish pedigree (c.2272C/T, p.R758X) - were also 
investigated (Van den Ouweland et al., 2011; Grossmann et al., 2013). Haplotype 
analysis of the Spanish patients with MFT1, as well as Dutch patients with FC and an 
Austrian patient with BSS was performed to investigate whether the same or 
different mutational events are responsible for the development of these cases.  
The surrounding polymorphisms were examined upstream and downstream 
from the mutation (c.2272C/T, p.R758X) by direct sequencing. The using primers 
sequences obtained from Primer3 (http://primer3.ut.ee/) and listed in Table 4.  
 
Primer 5'-3' sequence 
CYLD-I17-F ACT CTG TGA CCT CTA GGT GCT G 
CYLD-I17-R CAT GAC CAT TTC ATA CAC ATT GG 
CYLD-I17/1a-F GCT GCC AAA GAA AAC ACC A 
CYLD-I17/1a-R GGC ACA CCA GCA CCT AGA G 
CYLD-I17/1b-F GAA TGT TAA CCA GAG GAG AAT GG 
CYLD-I17/1b-R GGC AGA AGA TAA CCA CTG TCA AT 
CYLD-I17/1c-F GCG TTC CCA CAA TTC AGC A 
CYLD-I17/1c-R AGC TTG GTG TTT TCT TTG GCA 
CYLD-I17/1d-F TGA CAG TGG TTA TCT TCT GCC A 
CYLD-I17/1d-R CCA CAT ATC CGG CAC TGT CT 
Table 4. The list of primers used for the haplotype analysis. 
 
The results demonstrated that the Spanish and the Dutch pedigrees carry the 
same haplotype, whereas the Austrian patient carries a different haplotype. Thus, it 
can be assumed that different mutational events are responsible for the development 
of the Austrian case and the Spanish and Dutch cases (Table 5). 
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Nationality 
 
Spanish Dutch Austrian 
  
II/1 II/2 III/1 
   
  
healthy symptomatic symptomatic symptomatic symptomatic symptomatic 
Polymorphism 
ID 
Frequent 
allele 
      
rs35072258  TC/-  TCTC  TCTC  TCTC  TCTC  TCTC  TCTC  
rs11866167  C/A  CC  CC  CC  CC  CC  CC  
rs111543527  T/C  TT  TT  TT  TT  TT  TT  
rs72796392  T/C  TT  TT  TT  TT  TT  TT  
rs141129479  A/G  AA  AA  AA  AA  AA  AA  
rs146946436  A/G  AA  AA  AA  AA  AA  AA  
rs185111122  T/C  TT  TT  TT  TT  TT  TT  
rs149201712  AC/-  ACAC  ACAC  ACAC  ACAC  ACAC  ACAC  
rs368656359  G/A  GG  GG  GG  GG  GG  GG  
rs137990687  G/A  GG  GG  GG  GG  GG  GG  
rs201757487  G/-  GG  GG  GG  GG  GG  GG  
rs10451132  G/T  GG  GG  GG  GG  GG  GT  
rs370702435  A/G  AA  AA  AA  AA  AA  AA  
CM001116 
rs121908388 
C/T  CC  CT  CT  CT  CT  CT  
rs199912760  G/A  GG  GG  GG  GG  GG  GG  
rs375106322  G/A  GG  GG  GG  GG  GG  GG  
r201860550  G/T  GG  GG  GG  GG  GG  GG  
rs149502055  C/T  CC  CC  CC  CC  CC  CC  
rs376795685  G/A  GG  GG  GG  GG  GG  GG  
rs144013604  A/G  AA  AA  AA  AA  AA  AA  
rs75157714  G/A  GG  GG  GG  GG  GG  GG  
rs201233994  AT/-  AT  AT  AT  AT  AT  AT  
rs200973965  ATAC/-  ATAC  ATAC  ATAC  ATAC  ATAC  ATAC  
rs77528321  T/C  TT  TT  TT  TT  TT  TT  
rs146702654  T/-  TT  TT  TT  TT  TT  TT  
rs6145827  ACACAC/-  
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
rs3064638  ACACAC/-  
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
ACACAC 
- -  
rs73584492  A/G  AA  AA  AA  AA  AA  AA  
rs190892314  A/G  AA  AA  AA  AA  AA  AA  
rs200678983  C/T  CC  CC  CC  CC  CC  CC  
rs76797023  A/T  AA  AA  AA  AA  AA  AA  
rs77678929  T/A  TT  TT  TT  TT  TT  TT  
rs376799359  A/T  AA  AA  AA  AA  AA  AA  
rs201103123  C/T  CC  CC  CC  CC  CC  CC  
Table 5. Haplotype analysis of Spanish, Dutch and Austrian patients carrying the 
same recurrent nonsense mutation. (Farkas et al., 2016) 
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3.2.3. Genetic investigation of the Hungarian pedigree from Szekszárd 
 
The coding regions (exon 9-20) and the flanking introns of the CYLD gene 
were amplified. Primers were used as displayed on the UCSC Genome Browser 
(www.genome.ucsc.edu) (Table 3). The results of PCR were checked by agarose gel 
electrophoresis and DNA sequencing was performed.  
Direct sequencing of the coding regions and the flanking introns of the CYLD 
gene revealed a nonsense mutation (c.2806C>T, p.Arg936X) previously described by 
Bignell et al. in exon 20. The investigated affected family members of the Hungarian 
BSS pedigree carried the mutation in heterozygous form (Figure 17a), while the 
available, clinically unaffected family members and the unrelated healthy controls 
carried the wild type sequence (Figure 17b). 
 
 
Figure 17. The DNA sequence of the affected patients shows a heterozygous single 
nucleotide substitution: c.2806C>T, p.Arg936X (a). Wild-type sequence of the CYLD 
gene. (Nagy et al., 2013) 
 
3.2.4. Haplotype analysis of the Hungarian pedigree from Szekszárd and the 
Anglo-Saxon pedigree 
 
Based on the literature, an Anglo-Saxon BSS pedigree from the north of 
England also carried the same nonsense mutation (c.2806C>T, p.Arg936X), that was 
identified the Hungarian pedigree from Szekszárd. Since this nonsense mutation is 
present in an Anglo-Saxon pedigree, I planned to perform the haplotype analysis of 
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the two geographically distant pedigrees to reveal whether the mutation they carry is 
the result of two independent mutational events or they are carrying the same 
founding mutation.  
The surrounding polymorphisms were examined upstream and downstream 
from the mutation (c.2806C>T, p.Arg936X) by direct sequencing. The using primers 
sequences obtained from Primer3 (http://primer3.ut.ee/) and listed in Table 6.  
 
Primer név Bázissorrend (5'-3') 
CYLD-I19/1-F GCA TTA ACA ACC TTG CTA GCT GA 
CYLD-I19/1-R ATG GTG GCA TAT GCG TGT AG 
CYLD-I19/2-F TCA CAC CCC AGA GCA CCT 
CYLD-I19/2-R GAG GTA AGC CCC CAA CCT 
CYLD-I20/1-F TGC ATG TAC CAG AGT CCA ACA 
CYLD-I20/1-R AAG AGG CTT TAA ACT TCC ACA A 
CYLD-I20/2-F AAT GGG GCA AAG TAA ATT GAT G 
CYLD-I20/2-R GAG AAT GCA CAT TCC ACA GC 
Table 6. The list of primers used for the haplotype analysis. 
 
As the result of the examination, in the case of the Hungarian pedigree from 
Szekszárd, two polymorphisms (rs2160683, rs115042932) were found, which were 
inherited linked to the mutation in the CYLD gene (Table 7). Thus all of the clinically 
affected family members carried the AGT allele determined by these two 
polymorphisms and the mutation. The AGT allele was not present in the unaffected 
family members. 
In the case of the Anglo-Saxon BSS pedigree, I examined whether the AGT 
allele (rs2160683, rs115042932, CM001120) identified in the Hungarian pedigree is 
carried by the affected family members. The results of the haplotype analysis showed 
that the Anglo-Saxon BSS pedigree did not carry the AGT allele, which means that 
the same nonsense mutation was the result of two independent mutational events in 
the two geographically distant pedigrees (Table 8). Thus this part of the CYLD gene 
could be a mutational hotspot. 
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SNP  
Hungarian 
affected 
patient 
(V/2) 
Hungarian 
affected 
patient 
(V/11) 
Hungarian 
affected 
patient 
(V/12) 
Hungarian 
unaffected 
patient 
(VI/10) 
rs 28705891 C/T CC CC CC CC 
rs 28654666 T/C TT TT TT TT 
rs 112993837 C/T CC CC CC CC 
rs 60077744 G/A GG GG GG GG 
rs 2160683 T/A TA AA TA TT 
rs 115042932 C/G CG CG CG CC 
rs117998712 C/C CC CC CC CC 
CM001120 C/T CT CT CT CT 
rs 116979331 G/A GG GG GG GG 
rs 74822565 G/T GG GG GG GG 
rs 117713908 A/G AA AA AA AA 
rs 3743781 A/G AA AA AA AA 
rs 117537927 G/A GA GG GG GG 
rs 116971974 A/C AA AA AA AA 
rs 114552144 A/G AA AA AA AA 
Table 7. Results of the genotyping of the surrounding common polymorphisms. 
 
SNP 
 
Hunarian
affected 
patient 
(V/2) 
Hunarian
affected 
patient 
(V/11) 
Hunarian
affected 
patient 
(V/12) 
Anglo-
Saxon 
affected 
patient 
(IV/1) 
Anglo-
Saxon 
affected 
patient 
(IV/2) 
rs 2160683 T/A TA AA TA TT TT 
rs 115042932 C/G CG CG CG CC CC 
rs 117998712 C/T CC CC CC CC CC 
CM001120 C/T CT CT CT CT CT 
Table 8. Genotyping of the surrounding, common polymorphisms demonstrated that 
the same mutation carried by the two geographically distant pedigrees is surrounded 
by different haplotypes and was the result of two independent mutational events 
(Nagy et al., 2013). 
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3.2.5. Genetic investigation of the Hungarian pedigree from Szeged 
 
The coding regions (exon 9-20) and the flanking introns of the CYLD gene 
were amplified. Primers were used as displayed on the UCSC Genome Browser 
(www.genome.ucsc.edu) (Table 3). The results of PCR were checked by agarose gel 
electrophoresis and DNA sequencing was performed.  
Mutation analysis with direct sequencing of the coding regions of the CYLD 
gene revealed a novel missense mutation (c.2613C>G p.His871Gln) located in exon 
19, in heterozygous form in both affected patients (Figure 18a). This mutation could 
not be identified in any of the clinically unaffected family members or in the 
screened 95 Hungarian generally healthy controls (Figure 18b).  
 
 
Figure 18. The DNA sequence of the affected patients shows a heterozygous single 
nucleotide substitution c.2613C>G, p.His871Gln (a). Wild-type sequence of the 
CYLD gene (b). (Nagy et al., 2012) 
 
The mutation is situated in a highly conserved region of the CYLD gene 
(Figure 19), encoding a histidine-box structure, which is part of a larger structure 
forming the ubiquitin-specific protease (USP) domain. This novel mutation leads to a 
change from histidine to glutamine at position 871. Interestingly, this position in the 
amino acid sequence change is localized within an active site where phosphorylation 
takes place (www.uniprot.org; Accession No: Q9NQC7), suggesting a putative role 
for this amino acid change in the function of the USP domain. 
(a) 
(b) 
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Figure 19. Comparison of the sequences of the CYLD gene among different species 
demonstrated that the c.2613C>G, p.His871 mutation is located in a highly 
conserved region, which forms part of a histidine box. (Nagy et al., 2012) 
 
3.2.6. Functional investigation of the Hungarian pedigree from Szeged 
 
To reveal the function of this novel missense mutation (c.2613C>G, 
p.His871Gln), I studied the known CYLD-regulated pathways. CYLD protein is 
known to directly interact with the NF-κB signaling NEMO protein. Functional 
analysis was performed on fibroblasts isolated from biopsy samples of the patients 
affected by Brooke-Spiegler syndrome (n=2) and from healthy individuals (n=2) 
(Figure 20). 
 
 
Figure 20. Normal human (a, b) and CYLD mutant human (c, d) fibroblasts. 
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NEMO protein was immunoprecipitated from fibroblasts of the BSS patient 
and healthy controls (anti-human NEMO mouse antibody; BD Pharmingen). After 
loading equal amounts of the immunoprecipitated NEMO, Western blot was 
performed to detect the ubiquitination of the loaded samples. My data suggest that 
decreased NEMO expression is associated with its altered deubiquitination, NEMO 
immunoprecipitated from fibroblasts carrying the CYLD mutation demonstrated 
significantly higher ubiquitination than NEMO immunoprecipitated from control 
fibroblasts (Figure 21). 
 
 
Figure 21. Semi-quantitative analysis of the Western blotting demonstrated 
increased ubiquitination of NEMO immunporecipitated from fibroblasts of BSS 
patients compared to healthy fibroblasts. (Nagy et al., 2012) 
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4. DISCUSSION 
 
4.1. Comparison of the patient suffering from LEOPARD syndrome with the 
literature 
 
 I investigated a 51-year-old Hungarian male patient suffering from 
LEOPARD syndrome. Genetic screening of the PTPN11 gene was performed. The 
affected patient carries one of the most common missense mutation (c.836A/G; 
p.Tyr279Cys) in heterozygous form of the PTPN11 gene. The unrelated healthy 
controls (n=30) carried the wild type sequence. All the investigated relatives were 
clinically unaffected suggesting the presence of a de novo mutation in the patient.  
The p.Tyr279Cys mutation has previously been reported in 47 different LS 
patients with Italian, French, Spanish, German, Estonian, Bosnian, Chinese Han, 
South-Korean, Japanese and Australian origin (Begić et al., 2014; Froster et al., 
2003; Keren et al., 2004; Kim et al., 2011; Martínez-Quintana et al., 2012; Paradisi 
et al., 2005; Sarkozy et al., 2004; Tang et al., 2009; Uçar et al., 2006; Wang et al., 
2014; Yoshida et al., 2004). Thus this missense mutation is a worldwide recurrent 
missense mutation. Among the reported LS cases there are ones with de novo 
mutation (Kim et al., 2011; Wang et al., 2014) and others, in which the disease show 
familial clustering and affects multiple family members in multiple generations 
(Begić et al., 2014; Froster et al., 2003). These data suggest a mutational hotspot in 
the PTPN11 gene. 
The most common symptom, which was present in 46 (96%) out of 48 
patients is the presence of multiple lentigines. Further skin abnormality such as the 
development of café-au-lait spots were observed in only 22 (46%) patients. Besides 
the characteristic multiple lentigines, some of the facial anomalies were also very 
common among these patients: ocular hypertelorism was detected in 40 (83%) 
patients, palpebral ptosis in 32 (67%) patients and dysmorphic ears in 31 (65%) ones. 
Besides these common ectodermal abnormalities, patients with the p.Tyr279Cys 
PTPN11 mutation have a great chance to develop cardiovascular anomalies. 
Hypertrophic cardiomyopathy was diagnosed in 25 (52%) patients. Although short 
stature was previously reported to be frequently associated with the p.Tyr279Cys 
phenotype, it was present only in 19 (40%) patients out of 48. Regarding the other 
side of the spectrum, the p.Tyr279Cys mutation is rarely associated with deafness, 
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which was reported in 12 (25%) patients. Moreover this analysis identified that 
certain symptoms - such as cryptorchidism, macrocephaly, horse kidney, 
hydrothorax, myelodysplasia and umbilical hernia - are rarely associated with the 
p.Tyr279Cys phenotype. In one of the 48 LS patients with the recurrent p.Tyr279Cys 
PTPN11 mutation, Marfan syndrome was also present, which is probably a rare 
independent association (Tang et al., 2009) (Figure 22). 
Figure 22. Comparison of the frequency of the different symptoms detected in the 
p.Tyr279Cys phenotype. (Nemes and Farkas et al., 2015) 
 
The observed differences in the clinical symptoms of the 48 LS patients 
carrying the same missense mutation clearly demonstrate the wide phenotypic 
diversity and the variable expressivity of the disease. In general, multiple lentigines, 
café-au-lait macules, ocular hypertelorism, palpebral ptosis, dysmorphic ears and 
hertrophic cardiomyopathy are hallmarks of the p.Tyr279Cys PTPN11 mutation 
related phenotype.  
Further studies are needed to identify putative genetic, environmental or life 
style factors, which can modify the development of the clinical symptoms and 
responsible for the observed phenotypic diversity. The availability of the extended 
clinical findings about the p.Tyr279Cys mutation carriers is critical for promoting 
both our understanding of the disease and the development of causative therapies that 
will be more specific and effective than the symptomatic treatments currently 
available for LS patients.  
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4.2. Haplotype analysis of the patients carrying the recurrent nonsense 
p.Arg758X CYLD mutation represents a mutational hotspot in the gene  
 
I have identified a Spanish MFT1 pedigree with two affected family members 
(father and daughter). Direct sequencing of the CYLD gene revealed a worldwide 
recurrent nonsense mutation (c.2272C/T, p.R758X) in exon 17. Both patients carried 
the mutation in heterozygous form, whereas the unaffected family members and 
unrelated controls carried the wild-type sequence. 
A review of all previous studies reporting the same c.2272C/T, p.R758X 
nonsense mutation of the CYLD gene revealed that this mutation has also been 
detected in patients with BSS (Grossmann et al., 2013; Kazakov et al., 2009; Zhang 
et al., 2006), FC (Bignell et al., 2000; Van den Ouweland et al., 2011; Oiso et al., 
2004) and MFT1 (Grossmann et al., 2013; Kazakov et al., 2011). Thus, the 
c.2272C/T, p.R758X nonsense mutation of the CYLD gene can lead to the 
manifestation of any of the clinical variants in the disease spectrum caused by CYLD 
mutation, which is associated with high phenotypic diversity. Furthermore, this 
mutation has been detected in Caucasian American (Bignell et al., 2000), South 
African (Grossmann et al., 2013), Austrian (Grossmann et al., 2013; Kazakov et al., 
2011), Czech (Kazakov et al., 2009), Dutch (Van den Ouweland et al., 2011), 
Chinese (Zhang et al., 2006) and Japanese patients (Oiso et al., 2004) and is, thus, 
considered a recurrent worldwide mutation (Table 9). These data suggest that the 
c.2272C/T, p.R758X nonsense mutation is located at a mutational hotspot in the 
CYLD gene.  
 
CYLD cDNA CYLD protein 
Detected in patients 
with 
Nationality 
c.2272C>T p.R758X 
FC 
Caucasian American, Dutch, 
Japanese 
BSS 
Austrian, South African, 
Czech, Chinese 
MFT1 Austrian, Spanish 
Table 9. Summary of the geographical location and clinical manifestation of the 
recurrent p.R758X CYLD mutation. (Farkas et al., 2016) 
 
Previously reported Dutch (Van den Ouweland et al., 2011) and Austrian 
(Grossmann et al., 2013) cases carrying the same mutation were also investigated. To 
determine whether the worldwide recurrent p.R758X mutation of the CYLD gene is 
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the result of one or more independent mutational events, haplotype analysis was 
performed. The haplotype analysis of the Spanish, Dutch and Austrian patients 
demonstrated that, although the Spanish and the Dutch patients carry the same 
haplotype, the clinical appearance, MFT1 and FC, respectively, is different. These 
results suggest the importance of modifying genetic and/or environmental factors. In 
contrast with these, the Austrian patient carried a different haplotype than the 
Spanish and Dutch families. Thus, I assume the presence of the same mutation is the 
consequence of different mutational events. 
 
4.3. Haplotype analysis of the patients carrying the recurrent nonsense 
p.Arg936X CYLD mutation represents a mutational hotspot in the gene  
 
A large Hungarian BSS pedigree carrying a nonsense mutation (c.2806C>T, 
p.Arg936X) of the CYLD gene was investigated. This mutation was first reported by 
Bignell et al. (2000) and later by Bowen et al. (2005) in a European and a Canadian 
BSS pedigree. 
This nonsense p.Arg936X mutation was present in an Anglo-Saxon BSS 
pedigree, as well, therefore haplotype analysis was performed to elucidate whether 
the mutation they carry is the result of the same or two independent mutational 
events. Haplotype analysis of the Hungarian and the Anglo-Saxon BSS pedigrees 
demonstrated that the same mutation carried by the two geographically distant 
pedigrees was the result of two independent mutational events. I hypothesize that 
these positions may be mutational hotspots on the CYLD gene. Notably these 
hotspots are based within the coding sequence of the gene that encodes for the 
catalytic residues of CYLD, suggesting a dominant negative effect may be important 
in manifesting a phenotype.  
It is also interesting to note, that I found huge differences in the severity of 
the symptoms between the investigated Hungarian and the Anglo-Saxon BSS 
pedigrees despite the fact that the affected members are carrying the same mutation. 
There are previous studies in the literature, which reported huge phenotypic 
heterogeneity even within the same BSS pedigrees (Scheinfeld et al., 2003; Rajan et 
al., 2009), and raised the putative role of either environmental factors or modifying 
genes, which influence the clinical phenotype of the BSS patients (Bignell et al., 
2000).  
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4.4. The functional analysis of the newly identified missense mutation represents 
a disease-causing mutation in the CYLD gene  
 
I identified a novel missense mutation (c.2613C>G, p.His871Gln) of CYLD 
gene in a Hungarian BSS pedigree. CYLD protein has a role in the regulation of 
many signaling pathways, such as NF-κB signaling pathway throuhg the 
deubiquitination of NEMO protein as its interaction partner. I performed functional 
analysis to examine the role of the new mutation and measured ubiquitination of 
NEMO after immunoprecipitation and found an increased level of ubiquitination of 
the NEMO protein in fibroblasts carrying the novel CYLD mutation. Based on the 
results I suppose that this novel mutation through the increased ubiquitination of 
NEMO leads to decreased NEMO expression and as a consequence may influence 
the NF-κB pathway.  
Identification of the underlying mutation may have a considerable impact on 
family planning since it offers the possibility of prenatal mutation screening. Further 
studies are needed to elucidate the exact mechanism of the development of BSS 
symptoms. Since BSS displays only skin tumors, and mainly appendageal tumor 
formations, it may be an appropriate model for the development of novel gene 
therapy methods. 
 
4.5. Mutations on the CYLD gene 
 
To date, a total of 95 mutations have been published for the CYLD gene 
(Figure 23), and the individuals carrying these mutations present with phenotypic 
features of BSS, FC and/or MFT1.  
The majority of the CYLD mutations (98%) were reported in coding regions. 
Distribution of the mutations within exons is unequal: 99% of the mutations are 
located within exons 9–20. The majority of the sequence changes are frameshift 
(48%), nonsense (27%), missense (12%) or splice-site (11%) mutations, however, 
two in-frame deletions have also been reported. 
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Figure 23. CYLD gene mutations identified to date. (Nagy et al., 2014) 
 
Approximately half of the identified CYLD mutations (48%) are frameshift 
mutations arising from the insertion or deletion of a small number of nucleotides. 
The majority of these changes lead to the formation of premature stop codons 
causing truncation and, thus, the dysfunction of the CYLD protein. Frameshift 
mutations are unequally distributed in the CYLD gene: one third are located within 
the region spanning exons 5–11 (Bignell et al., 2000; Grossmann et al., 2013; Saggar 
et al., 2008; Nasti et al., 2009; Ying et al., 2012; Liang et al., 2008; Zheng et al., 
2004), whereas the rest (66%) occur within the region spanning exons 12–20 
(Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Lv et al., 2008; 
Saggar et al., 2008; Oiso et al., 2004; Reuven et al., 2013; Chen et al., 2011; Salhi et 
al., 2004; Melly et al., 2012; Heinritz et al., 2006). Exon 17 is a mutational hotspot, 
containing 20% of all identified frameshift mutations (Bignell et al., 2000; Bowen et 
al., 2005; Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 
2004). Only a quarter of the frameshift mutations (27%) are recurrent (Sima et al., 
2010; Poblete et al., 2002; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 
2013; Saggar et al., 2008; Oiso et al., 2004; Scheinfeld et al., 2003; Hester et al., 
2013).  
Nonsense mutations causing truncation and, thus, CYLD protein dysfunction 
are also common, accounting for one quarter (27%) of the CYLD mutations identified 
so far. The distribution of nonsense mutations is also unequal in the CYLD gene. One 
third of the nonsense mutations occur within the region spanning exons 9–11 (Sima 
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et al., 2010; Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos 
et al., 2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den 
Ouweland et al., 2011; Kazakov et al., 2009; Almeida et al., 2008), while the 
majority (72%) are located within the region spanning exons 12–20 (Sima et al., 
2010; Bignell et al., 2000; Zhang et al., 2004; Young et al., 2006; Oranje et al., 
2008; Bowen et al., 2005; Grossmann et al., 2013; Oiso et al., 2004; Kazakov et al., 
2009; Nagy et al., 2013; Nagy et al., 2012; Zheng et al., 2004; Chen et al., 2011; 
Almeida et al., 2008). This latter region does not seem to contain a further mutational 
hotspot. It is of interest to note that 25% of the identified nonsense mutations affect 
glutamine amino acid residues within the CYLD protein, replacing them with stop 
codons (Sima et al., 2010; Bignell et al., 2000; Grossmann et al., 2013; Zheng et al., 
2004; Chen et al., 2011; Almeida et al., 2008). Nearly half of the nonsense mutations 
(40%) are recurrent (Sima et al., 2010; Bignell et al., 2000; Oranje et al., 2008; 
Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; 
Kacerovska et al., 2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Oiso et 
al., 2004; Zhang et al., 2006; Kazakov et al., 2009; Kazakov et al., 2011; Nagy et al., 
2013; Zheng et al., 2004; Chen et al., 2011). 
Missense mutations account for 12% of all mutations identified on the CYLD 
gene. The distribution of missense mutations is also unequal on the CYLD gene: all 
are located within the region spanning exons 12–20 (Sima et al., 2010; Hu et al., 
2003; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 
2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; 
Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; 
Wang et al., 2010; Zuo et al., 2007). Only a quarter (27%) of these are recurrent 
mutations (Sima et al., 2010; Hu et al., 2003; Grossmann et al., 2013; Saggar et al., 
2008; Kazakov et al., 2009).  
Splice-site mutations account for 11% of all mutations. The distribution of the 
splice-site mutations is also unequal: all of them occur within the region spanning 
exons 10–18 (Bignell et al., 2000; Grossmann et al., 2013; Kacerovska et al., 2013; 
Van den Ouweland et al., 2011; Kazakov et al., 2011; Nasti et al., 2009; Ying et al., 
2012; Liang et al., 2008; Huang et al., 2009; Ly et al., 2004). Less than a quarter 
(18%) are recurrent (Bignell et al., 2000; Grossmann et al., 2013; Van den Ouweland 
et al., 2011; Kazakov et al., 2011).  
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In addition, two in-frame deletions have also been reported: these mutations 
are located within exons 19 and 20. Both of them lead to the development of the FC 
clinical variant (Van den Ouweland et al., 2011).  
 
4.6. Distribution of the mutations in the CYLD protein 
 
The protein encoded by the CYLD gene (GenBank NP_056062) exhibits 
deubiquitinase activity. The N-terminal of the CYLD protein can be divided into two 
regions based on the occurrence of the mutations: no mutations have been detected in 
the region encoded by exons 4 and 5, whereas the region encoded by exons 5–11 
contains approximately one fifth (18%) of the mutations identified to date. The N-
terminal of the CYLD protein contains three cytoskeleton-associated glycine rich 
domains (CAP-GLY), at which the CYLD protein connects to microtubules (Gao et 
al., 2008). The N-terminal of the CYLD protein is highly conserved through 
evolution. Mostly frameshift and nonsense mutations occur in this region, as well as 
the two known splice-site mutations (Sima et al., 2010; Bignell et al., 2000; Bowen 
et al., 2005; Grossmann et al., 2013; Kacerovska et al., 2013; Saggar et al., 2008; 
Kazakov et al., 2009; Nasti et al., 2009; Liang et al., 2008; Zheng et al., 2004; 
Almeida et al., 2008; Ly et al., 2004). Most frameshift mutations occur in the first 
(amino acids 127 to 203) and the third (amino acids 472 to 540) CAP-GLY domains, 
whereas most of the nonsense and splice-site mutations occur in the region of the 
third CAP-GLY domain. Missense mutation has not been detected at the N-terminal 
of the CYLD protein (Figure 24).  
 
 
Figure 24. Distribution of the most common type mutations in the CYLD protein. 
(Nagy et al., 2014) 
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The CYLD gene has changed relatively little through evolution: the similarity 
between the human and mouse genes is 94%, and the homology is especially high at 
the 3' end of the gene. This region of the CYLD protein, encoded by exons 12–20, 
contains the ubiquitin-specific protease domain that is responsible for the 
deubiquitinase activity of the protein. This region contains the majority (82%) of 
identified CYLD mutations, including frameshift (72%), nonsense (72%) and splice-
site (81%) mutations as well as all known missense mutations (Figure 24). 
Functional studies of the identified mutations suggest that mutations of this region 
may decrease the deubiquitinase activity of the CYLD protein (Nagy et al., 2012).  
 
4.7. Genotype and phenotype correlations in case of patients carrying CYLD 
mutation 
 
Genotype–phenotype correlations are difficult to establish, as all types of 
known CYLD mutation – frameshift, nonsense, missense and splice-site – lead to the 
development of each clinical variant of the CYLD mutation-caused spectrum. 
Frameshift mutations of the CYLD gene have been identified for all clinical 
variants of the CYLD mutation-caused spectrum. Interestingly, most frameshift 
mutations occur in the region of exon 17 (Bignell et al., 2000; Bowen et al., 2005; 
Grossmann et al., 2013; Lv et al., 2008; Saggar et al., 2008; Oiso et al., 2004). 
Nonsense mutations of the CYLD gene exhibit the largest phenotypic 
diversity. Some nonsense mutations (i.e., c.1112C/A p.S371X, c.2272C/T p.R758X 
and c.2806C/T p.R936X) have been detected in patients diagnosed with FC, BSS or 
MFT1 (Bignell et al., 2000; Bowen et al., 2005; Grossmann et al., 2013; Linos et al., 
2011; Lv et al., 2008; Kacerovska et al., 2013; Saggar et al., 2008; Van den 
Ouweland et al., 2011; Oiso et al., 2004; Zhang et al., 2006; Kazakov et al., 2009; 
Kazakov et al., 2011; Nagy et al., 2013). As many recurrent nonsense mutations are 
due to de novo events, their frequency and location indicates mutational hotspots on 
the CYLD gene (Bignell et al., 2000; Nagy et al., 2013). Patients carrying the same 
nonsense mutation from different mutational events often exhibit extreme differences 
in their clinical manifestations (Nagy et al., 2013). These differences might be the 
consequences of yet unknown genetic factors that modify the development of the 
phenotype. Nonsense mutations are also responsible for the most variable expression 
within families (Bowen et al., 2005; Zhang et al., 2006; Nagy et al., 2013). These 
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differences might be explained by environmental and/or lifestyle factors. Further 
studies are needed to elucidate putative genetic, environmental or lifestyle factors 
that are responsible for the observed great variation in phenotype.  
Missense mutations of the CYLD gene are more frequently associated only 
with MFT1 (73%) than the other types of mutations (Sima et al., 2010; Hu et al., 
2003; Grossmann et al., 2013; Linos et al., 2011; Lv et al., 2008; Kacerovska et al., 
2013; Saggar et al., 2008; Van den Ouweland et al., 2011; Kazakov et al., 2009; 
Nagy et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; 
Wang et al., 2010; Zuo et al., 2007). Missense mutations also lead to the 
development of milder phenotype (Nagy et al., 2012). This observation might be 
explained by the fact that missense mutations are distributed differently than the 
other types of mutations: they are located only between exons 12–20 and not at all in 
the 5' end. In general, missense mutations are associated with low phenotypic 
diversity, as the majority of missense mutations result in the MFT1 phenotype (Nagy 
et al., 2012; Zheng et al., 2004; Almeida et al., 2008; Espana et al., 2007; Wang et 
al., 2010; Zuo et al., 2007).  
Splice-site mutations of the CYLD gene can lead to the development of any 
clinical variant of the CYLD mutation-caused spectrum, but little is known about 
their phenotypic significance (Kacerovska et al., 2013; Van den Ouweland et al., 
2011; Nasti et al., 2009; Liang et al., 2008; Huang et al., 2009). 
The comparison of CYLD gene mutations and the observed clinical variation 
of the patients have already revealed significant genotype–phenotype correlations: 
nonsense mutations are associated with the highest phenotypic diversity and 
recurrence rate, while missense mutations are associated with mild symptoms and are 
strongly associated with the MFT1 phenotype. Future efforts might provide insight 
into the clinical significance of frameshift and splice-site mutations and further 
elucidate the mechanism of the different phenotypic variants of the CYLD mutation-
caused spectrum. Careful investigation of genotype–phenotype correlations are 
necessary to promote better understanding of the BSS, FC and MFT1 clinical 
variants and provide insight into the underlying molecular mechanisms. Genetic 
screening and the identification of disease-causing mutations have already had a 
significant impact on prenatal and preimplantation genetic diagnosis for family 
planning. 
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4.8. Geographical occurrence of CYLD-mutation caused disease spectrum 
 
Mutations of the CYLD gene have been reported among patients with Irish, 
Japanese, Spanish, German, Algerian, Turkish, Hungarian, Slovakian, Italian, 
Scandinavian, Taiwanese, Turkish, Canadian and African backgrounds (Bowen et 
al., 2005; Kacerovska et al., 2013; Saggar et al., 2008; Nagy et al., 2013; Nagy et al., 
2012; Nasti et al., 2009; Salhi et al., 2004; Huang et al., 2009; Amaro et al., 2010). 
However, the majority of the published mutations are reported from the UK, USA 
and China (Bignell et al., 2000; Lv et al., 2008; Ying et al., 2012; Liang et al., 2008; 
Zheng et al., 2004; Chen et al., 2011; Wang et al., 2010; Zuo et al., 2007).  
Comparing the ethnicity and the reported allelic variants, geographical 
differences can be observed. The clinical phenotype of MFT1 was observed in 
African, African American, Taiwanese, Algerian, Turkish, Italian and Spanish 
patients though the most of it has been reported from China (Lv et al., 2008; 
Kacerovska et al., 2013; Liang et al., 2008; Zheng et al., 2004; Chen et al., 2011; 
Wang et al., 2010; Zuo et al., 2007). The FC clinical variant was present in Dutch, 
Italian and Irish patients, however, the majority have been reported from the UK and 
from the USA (Bignell et al., 2000; Bowen et al., 2005; Nasti et al., 2009). The 
clinical phenotype of BSS was detected in patients from Hungary, Slovakia, 
Austrian, Italy, Scandinavia, Spain, Canada and the majority – similarly to FC – is 
coming from the UK and the USA (Bignell et al., 2000; Bowen et al., 2005; 
Kacerovska et al., 2013; Nagy et al., 2013; Nagy et al., 2012; Nasti et al., 2009).  
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5. SUMMARY 
 
In my thesis, I have summarized the genetic and functional investigations in 
stigmatizing rare diseases: LS and the clinical variants of the CYLD mutation-caused 
disease spectrum namely MFT1, FC and BSS.  
LS is a rare monogenic disorder. The name is an acronym of its major 
features such as multiple lentigines, electrocardiographic conduction defects, ocular 
hypertelorism, pulmonary stenosis, abnormalities of genitalia, retardation of growth 
and sensorineural deafness. LS develops due to mutations in the protein-tyrosine 
phosphatase nonreceptor-type 11, PTPN11. I have investigated a 51-year-old 
Hungarian male patient affected by LS. Direct sequencing of the PTPN11 gene 
revealed a worldwide recurrent missense mutation (c.836A/G; p.Tyr279Cys), which 
has been previously identified in 47 LS patients. Comparison of the clinical 
phenotypes of our patient and the ones reported in the literature demonstrates great 
phenotypic diversity despite of the same genotype.  
MFT1 is a rare monogenic skin disease with autosomal dominant inheritance, 
is characterized by the development of multiple skin-colored papules on the central 
area of the face, frequently occurring in the nasolabial area. The disease is associated 
with various mutations in the CYLD gene that are also responsible for the 
development of FC and BSS. I have identified a Spanish MFT1 pedigree with two 
affected family members (father and daughter). Direct sequencing of the CYLD gene 
revealed a worldwide recurrent heterozygous nonsense mutation (c.2272C/T, 
p.R758X) in the patients. This mutation has already been detected in patients with all 
three clinical variants – BSS, FC and MFT1 – of the CYLD-mutation spectrum. 
Haplotype analysis was performed for the Spanish patients with MFT1, Dutch 
patients with FC and an Austrian patient with BSS, all of whom carry the same 
heterozygous nonsense p.R758X CYLD mutation. The results demonstrated that 
different mutational events are responsible for the development of the Austrian case 
and the Spanish and Dutch cases. These results indicate that this position is a 
mutational hotspot in the gene and that patients carrying the mutation exhibit high 
phenotypic diversity. 
BSS is an autosomal dominant rare monogenic skin disease characterized by 
skin appendage tumors including cylindromas, trichoepitheliomas, and/or 
spiradenomas. I investigated a Hungarian BSS pedigree with Bukovinian 
48 
 
(Romanian) origin containing 21 affected family members spanning 7 generations. 
Direct sequencing of the coding regions of the CYLD gene revealed a nonsense 
mutation (c.2806C>T, p.Arg936X) in exon 20. Since this nonsense mutation is 
present in an Anglo-Saxon pedigree from the north of England, I performed the 
haplotype analysis of the two geographically distant pedigrees and revealed that the 
mutation they carry is the result of two independent mutational events. The results 
suggest that this may be a mutational hotspot in the CYLD gene. Regarding the 
phenotypic features of the investigated pedigrees carrying the same nonsense 
mutation, I observed huge differences in the severity of the symptoms suggesting the 
presence of a yet unidentified modulatory factor. 
Another Hungarian BSS pedigree has been investigated with two affected 
members, father and daughter. Direct sequencing demonstrated a novel missense 
mutation (c.2613C>G; p.His871Gln) in exon 19 of the CYLD gene within the 
ubiquitin-specific protease domain of the encoded protein. Preliminary analysis has 
been performed to reveal the functional role of this novel mutation. Data suggest that 
this novel CYLD mutation leads to increased ubiquitination of NEMO through 
influencing deubiquitinating activity of the CYLD protein and thus may result in 
enhanced NF-κB signaling.  
CYLD protein is expressed in a wide range of human tissues, the reason why 
dysfunction manifests only in skin symptoms is still unclear. Moreover, patients 
carrying the same mutation from different mutational events often exhibit extreme 
differences in their clinical and histological manifestations. These differences might 
be the consequences of yet unknown genetic, environmental and/or lifestyle factors 
that modify the development of the phenotype.  
These investigations have great importance because they could be the basis of 
future genetic studies for the development of novel causative therapies that will be 
more specific and effective than the symptomatic treatments. Genetic screening and 
the identification of the disease-causing mutation have great significance for family 
planning in prenatal and preimplantation diagnosis.  
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7. ELECTRONIC DATABASE INFORMATION 
 
Ensemble Genome Browser (for the wild type sequencing data of the human 
genome, for the gene variation database regarding disease-causing and non-causing 
alterations and for the taxonomy analysis of the identified mutation) 
www.ensemble.org 
 
Online Mendelian Inheritance in Man (for the detailed information on the 
genetics, inheritance, clinical features and identified mutations in monogenic 
neurogenetic disorders) www.omim.org 
 
Orphanet Database (for the collection and detailed description of rare 
diseases) www.orpha.net 
 
UCSC Genome Browser, Primer3 (for the design of specific primers used 
to amplify the sequenced regions of the genes) http://genome.ucsc.edu/; 
http://bioinfo.ut.ee/primer3-0.4.0/ 
 
PubMed (for the literature search to identify the previously published cases) 
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Abstract LEOPARD syndrome (LS, OMIM 151100) is a
rare monogenic disorder. The name is an acronym of its
major features such as multiple lentigines, electrocardio-
graphic conduction defects, ocular hypertelorism, pul-
monary stenosis, abnormalities of genitalia, retardation of
growth and sensorineural deafness. LS develops due to
mutations in the protein-tyrosine phosphatase nonreceptor-
type 11, PTPN11. Here, we have investigated a 51-year-old
Hungarian male patient affected by LS. Direct sequencing
of the PTPN11 gene revealed a worldwide recurrent mis-
sense mutation (c.836A/G; p.Tyr279Cys), which has been
previously identified in 47 LS patients. Comparison of the
clinical phenotypes of our patient and the ones reported in
the literature demonstrates great phenotypic diversity
despite the same genotype.
Keywords LEOPARD syndrome  PTPN11 gene 
Worldwide recurrent missense mutation  Phenotypic
diversity  p.Y279C
Introduction
LEOPARD syndrome (LS, OMIM 151100)—a rare
monogenic disorder belonging to the family of neuro-car-
diofacio-cutaneous syndromes [16]—is inherited as an
autosomal dominant trait with full penetrance and variable
expressivity [3, 10]. The major features of LS include
multiple lentigines, electrocardiographic conduction
abnormalities, ocular hypertelorism, pulmonary stenosis,
abnormal genitalia, retardation of growth and sensorineural
deafness; this is why the syndrome is referred to as the
LEOPARD acronym [4, 10]. LS develops as a consequence
of mutations of the protein-tyrosine phosphatase nonre-
ceptor-type 11 (PTPN11) gene encoding a cytoplasmic
protein-tyrosine phosphatase (SHP-2), which regulates
intracellular signaling and controls several distinct devel-
opmental processes [15, 19]. In about 85 % of the cases, a
heterozygous missense mutation is detected in the exon 7,
12 or 13 [6, 11]. Among the so far identified missense
mutations, there are two (p.Tyr279Cys and p.Thr468Met),
which account for about 65 % of all LS cases worldwide
[6, 11].
Here, we report a Hungarian LS patient carrying the
most common p.Tyr279Cys heterozygous missense muta-
tion and compare his clinical features with the symptoms of
previously reported LS patients (n = 47), in whom the
same causative mutation was identified.
Patients and methods
Patients
A 51-year-old Hungarian male patient was admitted to the
cardiology unit of the Orosha´za Hospital (Orosha´za,
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Fig. 1 The clinical symptoms,
the pedigree of the patient and
the identified recurrent mutation
of the PTPN11 gene. On
examination, facial
dysmorphisms including ocular
hypertelorism, palpebral ptosis,
slight mandibular prognathism
and dysmorphic ears were
observed (a). Pigmentation
abnormalities such as multiple
lentigines (b) and cafe´-au-lait
spots (c) were also present on
the patient’s skin. On
electrocardiography a third-
degree atrioventricular block
was present (d). The patient was
born outside marriage. The
family members of his father
and mother were all clinically
unaffected individuals
suggesting (e). Direct
sequencing revealed a
heterozygous missense mutation
(c.836A/G; p.Tyr279Cys) in the
seventh exon of the PTPN11
gene. The patient carried the
mutation in heterozygous form
(f), while the unrelated controls
carried the wild-type sequence
(g)
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Hungary) with dizziness and palpitation. On investigation,
facial anomalies including ocular hypertelorism, palpebral
ptosis, dysmorphic ear, slight mandibular prog-
nathism(Fig. 1a) and pigmentation abnormalities such as
multiple lentigines (Fig. 1b) and cafe´-au-lait spots (Fig. 1c)
were also observed. Cardiology investigations revealed
third degree atrioventricular block (Fig. 1d). The patient is
deaf and dumb since he was born and mild growth as well
as mental retardations were also present. Urological
investigation revealed mild genital abnormalities such as
atrophic testes. These clinical symptoms suggested LS;
therefore, genetic screening of the PTPN11 gene was also
performed. The patient was born out of wedlock; however,
the family members of his father and his mother were
available for the clinical and genetic investigations
(Fig. 1e). All the investigated relatives were clinically
unaffected, suggesting the presence of a de novo mutation
in the patient.
Genetic investigations
Blood sample was taken from the patient and genomic
DNA isolated by a BioRobot EZ1 DSP Workstation (Qi-
agen; Godollo, Hungary). All the coding regions of the
PTPN11 gene and the flanking introns were amplified and
sequenced (primers were used as displayed on the UCSC
Genome Browser http://www.genome.ucsc.edu). The
investigation was approved by the Internal Review Board
of the University of Szeged. Written informed consent was
obtained from the patient, and the study was conducted
according to the Principles of the Declaration of Helsinki.
Results
Direct sequencing of the coding regions and the flanking
introns of the PTPN11 gene revealed a heterozygous mis-
sense mutation (c.836A/G; p.Tyr279Cys) in the seventh
exon (Fig. 1f). The clinically affected patient carried the
mutation in heterozygous form, while the unrelated healthy
controls carried the wild-type sequence (Fig. 1g).
Discussion
The investigated Hungarian LS patient carries one of the
most common missense mutation (p.Tyr279Cys) of the
PTPN11 gene. Functional studies demonstrated that the
p.Tyr279Cys heterozygous missense mutation of the
PTPN11 gene perturbs the switching of the SHP-2 pro-
tein between its catalytically inactive and active confor-
mation and engenders loss of SHP-2 catalytic activity
[18].
The p.Tyr279Cys mutation has previously been reported
in 47 different LS patients with Italian, French, Spanish,
German, Estonian, Bosnian, Chinese Han, South-Korean,
Japanese and Australian origin [1, 5, 8, 9, 12–14, 17, 20–
22]. Thus, this is a worldwide recurrent missense mutation.
Among the reported LS cases, there are ones with de novo
mutation [9, 21], and others in which the disease show
familial clustering and affects multiple family members in
multiple generations [1, 5]. These data suggest a mutational
hotspot on the PTPN11 gene.
Previous reports demonstrated that the p.Tyr279Cys
PTPN11 mutation is associated with short stature, deafness
and hypertrophic cardiomyopathy [6, 11]. The detailed
comparison of the clinical symptoms of the 48 LS patients
with the same causative mutation further complicated the
analysis of the genotype–phenotype correlations of this
mutation.
The most common symptom, which was present in 46
(96 %) out of 48 patients is the presence of multiple
lentigines (Fig. 2). Further skin abnormality such as the
development of cafe´-au-lait spots were observed in only 22
(46 %) patients. Besides the characteristic multiple
lentigines, some of the facial anomalies were also very
common among these patients: ocular hypertelorism was
detected in 40 (83 %), palpebral ptosis in 32 (67 %) and
dysmorphic ears in 31 (65 %) patients. Besides these
common ectodermal abnormalities, patients with the
p.Tyr279Cys PTPN11 mutation have a great chance to
develop cardiovascular anomalies. Hypertrophic car-
diomyopathy was diagnosed in 25 (52 %) patients.
Although short stature was previously reported to be fre-
quently associated with the p.Tyr279Cys phenotype, it was
present only in 19 (40 %) patients out of 48.
Regarding the other side of the spectrum, the
p.Tyr279Cys mutation is rarely associated with deafness,
which was reported in 12 (25 %) patients (Fig. 2). More-
over, our analysis identified that certain symptoms—such
as cryptorchidism, macrocephaly, horse kidney, hydrotho-
rax, myelodysplasia and umbilical hernia—are rarely
associated with the p.Tyr279Cys phenotype. In 1 of the 48
LS patients with the recurrent p.Tyr279Cys PTPN11
mutation, Marfan syndrome was also present, which is
probably a rare independent association [17].
The observed differences in the clinical symptoms of the
48 LS patients carrying the same missense mutation clearly
demonstrate the wide phenotypic diversity and the variable
expressivity of the disease. In general, multiple lentigines,
cafe´-au-lait macules, ocular hypertelorism, palpebral pto-
sis, dysmorphic ears and hypertrophic cardiomyopathy are
hallmarks of the p.Tyr279Cys PTPN11 mutation-related
phenotype. However, there is no similar analysis investi-
gating the most frequently associated clinical features in
LS patients carrying the other common, recurrent missense
Arch Dermatol Res (2015) 307:891–895 893
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mutation (p.Thr468 Met) of the PTPN11 gene; the pub-
lished reports suggest that the p.Thr468 Met mutation is
also associated with high phenotypic diversity [2, 7].
Further studies are needed to identify putative genetic,
environmental or lifestyle factors, which can modify the
development of clinical symptoms and responsible for the
observed phenotypic diversity. The availability of the
extended clinical findings about the p.Tyr279Cys mutation
carriers, as provided by this study, is critical for promoting
both our understanding of the disease and the development
of causative therapies that will be more specific and
effective than the symptomatic treatments currently avail-
able for LS patients.
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nonsense mutation detected in patients
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Abstract
Background: Multiple familial trichoepithelioma type 1 (MFT1; MIM 601606), a rare monogenic skin disease with
autosomal dominant inheritance, is characterized by the development of multiple skin-colored papules on the
central area of the face, frequently occurring in the nasolabial area. The disease is associated with various
mutations in the cylindromatosis (CYLD; MIM 605018) gene that are also responsible for familial cylindromatosis
(FC) and Brooke-Spiegler syndrome (BSS).
Methods: Recently we have identified a Spanish MFT1 pedigree with two affected family members (father and
daughter). Direct sequencing of the CYLD gene revealed a worldwide recurrent heterozygous nonsense mutation
(c.2272C/T, p.R758X) in the patients.
Results: This mutation has already been detected in patients with all three clinical variants – BSS, FC and MFT1 – of the
CYLD-mutation spectrum. Haplotype analysis was performed for the Spanish patients with MFT1, Dutch patients with
FC and an Austrian patient with BSS, all of whom carry the same heterozygous nonsense p.R758X CYLD mutation.
Conclusions: Our results indicate that this position is a mutational hotspot on the gene and that patients carrying the
mutation exhibit high phenotypic diversity.
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Background
Multiple familial trichoepithelioma type 1 (MFT1; MIM
601606) is an autosomal dominant condition characterized
by numerous firm skin-colored papules that are trichoe-
pitheliomas (follicular tumors). The tumors grow slowly in
size and number throughout life, often producing signifi-
cant cosmetic disfigurement.
MFT1, familial cylindromatosis (FC; MIM 132700)
and Brooke-Spiegler syndrome (BSS, MIM 605041) have
been independently mapped to chromosome 16q12-q13
by several groups [1–3]. First, FC was mapped to this re-
gion in 1995 [1], and its candidate gene, the CYLD gene,
was identified in 2000 [3]. Later BSS was mapped to the
same region in 2000 [4]. In the mapped region, the same
causative gene was identified in 2002 [5]. Regarding
MFT1, the same causative gene was identified in 2003
[6]. These genetic investigations supported the previous
clinical hypothesis, that MFT1 and FC might be the con-
sequence of the dysfunction of the same gene, since their
clinical symptoms can occur in the same patient or in
different patients within the same family [7].
In the mapped region, the cylindromatosis (CYLD)
gene [NM_015247] was identified as the causative gene
responsible for the development of these three diseases [3].
The gene encodes an enzyme with deubiquitinase activity,
which is involved in the post-translational modification
of its target proteins and removes Lys63-linked ubiquitin
chains [8]. The protein interacts with and negatively
regulates the TRAF2, TRAF6, NEMO and BCL3 proteins,
affecting the NF-ĸB signaling pathway [8].
Here we report a Spanish MFT1 pedigree with an af-
fected father and daughter, in whom we have identified the
recurrent p.R758X CYLD mutation. Previously reported
cases carrying the same mutation are reviewed to compare
the reported clinical phenotypes and to determine the geo-
graphical distribution of the mutation. Moreover, haplotype
analysis of the Spanish patients with MFT1, as well as
Dutch patients with FC and an Austrian patient with BSS
was performed to investigate whether the same or different
mutational events are responsible for the development of
these cases.
Methods
Patients
The Spanish MFT1 pedigree of Hispanic origin reported
here was identified in the Levant region of Valencia,
Spain. The 62-year-old father exhibited skin lesions that
developed progressively on the central area of the face
since the age of 14. Physical examination revealed mul-
tiple skin-colored papules measuring a few millimeters
and coalescing to form plaques in both nasolabial folds
(Fig. 1a), on the forehead, above the eyebrows and, to a
lesser extent, on the ears, on the back of the head and
on the back. Histological examination of one of the lesions
from the right eyebrow revealed multiple basaloid cell ag-
gregates with small keratinized cystic spaces surrounded
Fig. 1 Skin symptoms, histology findings and pedigree of a Spanish family with multiple familial trichoepithelioma type 1. Two affected family
members were identified. a The father presented skin-colored papules in the periorbital region, nose, nasolabial folds and upper lip. b Histological
features of trichoepithelioma were islands of basaloid cells with peripheral palisading and small horny cysts (hematoxylin-eosin staining; original
magnification × 10). c The daughter presented similar but smaller and fewer lesions in the nasolabial fold. d The pedigree of the investigated family.
Written informed consent was obtained from all participants to publish this article and its accompanying images
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by specific follicular stroma (Fig. 1b). These findings were
consistent with the diagnosis of trichoepithelioma (cribri-
form trichoblastoma). Subsequently several biopsies were
taken and all histological results supported the diagnosis
of trichoepithelioma. The patient has been followed for
24 years, during which time the lesions have increased
in number and size. Treatment consisted of block exci-
sion of multiple localized trichoepithelioma plaques in
the nasolabial fold. Other lesions were treated mainly
with electrocoagulation. The patient is currently receiving
CO2 laser treatment.
The patient’s only child, a 33-year-old daughter, has
lesions similar to those of her father but are fewer in
number (Fig. 1c). The lesions first appeared in both
nasolabial folds and, over time, began to appear on her
forehead, temples, ears and scalp. Trichoepithelioma
was confirmed with a biopsy of a lesion from the right
temple. The daughter has been treated with electro-
coagulation and cryotherapy, followed by 5 % imiquimod
cream. Trichoepitheliomas in the left nasolabial fold were
also treated with a single session of photodynamic therapy
which had to be discontinued after a few minutes due to
intense pain the area. A burn subsequently appeared in
the treated area and took weeks to heal. Trichoepithelio-
mas were resolved but new lesions subsequently appeared
in the same area. At present, the patient is receiving a
CO2 laser treatment and is exhibiting good tolerance and
acceptable aesthetic results. To date, no clinical or histo-
logical evidence for cylindromas or spiradenomas has
been observed in either the father or the daughter. No
other clinically affected member has been identified in this
pedigree (Fig. 1d).
The data for Dutch and Austrian patients is publically
available, and we did not take any samples from these
patients ourselves. The investigated Dutch patients were
previously reported by Van den Ouweland et al. [9].
Based on the development of cylindromas, these patients
were diagnosed with FC. Their detailed clinical description
is present in the report of Van den Ouweland et al. [9].
The investigated Austrian patient was previously reported
by Grossmann et al. [10]. Based on the development of
different skin appendage tumors, the diagnosis of BSS was
established. The detailed clinical description of the symp-
toms is available in the study of Grossmann et al. [10].
Genetic investigation
The enrollment of the Spanish patients into the genetic
investigations have been approved by the Clinical Re-
search Ethics Committee (CEIC) of Consorcio Hospital
General Universitario de Valencia. The performed gen-
etic investigation was approved by the Internal Review
Board of the University of Szeged, Szeged, Hungary.
Written informed consents have been obtained from all
the investigated subjects. The study was conducted ac-
cording to the Principles of the Declaration of Helsinki.
Blood samples for genetic analyses were taken from
the Spanish patients and from their clinically unaffected
family members, as well as from unrelated controls.
Genomic DNA was isolated with a BioRobot EZ1 DSP
Workstation (QIAGEN; Godollo, Hungary). The coding
regions of the CYLD gene and the flanking introns were
amplified and sequenced (primer sequences were obtained
from the UCSC Genome Browser, www.genome.ucsc.edu).
For haplotype analysis of the Spanish, Dutch and
Austrian patients, common polymorphisms (n = 33) were
genotyped from regions upstream (n = 20; rs199912760,
rs375106322, rs201860550, rs149502055, rs376795685,
rs144013604, rs75157714, rs201233994, rs200973965,
rs77528321, rs146702654, rs6145827, rs3064638,
rs73584492, rs190892314, rs200678983, rs76797023,
rs77678929, rs376799359, rs201103123) and downstream
(n = 13; rs370702435, rs10451132, rs201757487,
rs137990687, rs368656359, rs149201712, rs185111122,
rs146946436, rs141129479, rs72796392, rs111543527,
rs11866167, rs35072258) of the identified mutation. A
detailed list of the investigated polymorphisms is presented
in Table 1. Genotypes of the investigated polymorphisms
were determined with direct sequencing.
Results and discussion
Direct sequencing of the coding regions and the flanking
introns of the CYLD gene from the investigated Spanish
patients revealed a previously described nonsense mu-
tation in exon 17 (c.2272C/T, p.R758X, rs121908388).
This mutation results in a premature termination codon
causing truncation and, thus, dysfunction of the CYLD pro-
tein. Both patients carried the mutation in heterozygous
form (Fig. 2a), whereas the unaffected family members
and unrelated controls carried the wild-type sequence
(Fig. 2b, Additional file 1.). The identified mutation was
located in the ubiquitin-specific protease domain of the
CYLD protein (Fig. 2c).
Previously reported Dutch and Austrian cases carrying
the same mutation were also investigated in this study
[9, 10]. Haplotype analysis of the Spanish patients with
MFT1, the Dutch patients with FC and Austrian patients
with BSS was performed (Table 1.). Our results demon-
strated that the Spanish and the Dutch pedigrees carry
the same haplotype, whereas the Austrian patient carries
a different haplotype. Thus, it can be assumed that differ-
ent mutational events are responsible for the development
of the Austrian case and the Spanish and Dutch cases.
A review of all previous studies reporting the same
c.2272C/T, p.R758X nonsense mutation of the CYLD
gene revealed that this mutation has also been detected
in patients with BSS [10–12], FC [3, 9, 13] and MFT1
[10, 14]. Thus, the c.2272C/T, p.R758X nonsense mutation
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of the CYLD gene can lead to the manifestation of any of
the clinical variants in the disease spectrum caused by
CYLD mutation, which is associated with high phenotypic
diversity. Furthermore, this mutation has been detected in
Caucasian American [3], South African [10], Austrian
[10, 14], Czech [11], Dutch [9], Chinese [12] and Japanese
patients [13] and is, thus, considered a recurrent world-
wide mutation (Table 2.). These data suggest that the
c.2272C/T, p.R758X nonsense mutation is located at a
mutational hotspot in the CYLD gene.
Table 1 Haplotype analysis of Spanish, Dutch and Austrian patients carrying the same recurrent nonsense mutation
Nationality Spanish Dutch Austrian
II/1 II/2 III/1
Healthy Symptomatic Symptomatic Symptomatic Symptomatic Symptomatic
Polymorphism ID Frequent
allele
rs35072258 TC/- TCTC TCTC TCTC TCTC TCTC TCTC
rs11866167 C/A CC CC CC CC CC CC
rs111543527 T/C TT TT TT TT TT TT
rs72796392 T/C TT TT TT TT TT TT
rs141129479 A/G AA AA AA AA AA AA
rs146946436 A/G AA AA AA AA AA AA
rs185111122 T/C TT TT TT TT TT TT
rs149201712 AC/- ACAC ACAC ACAC ACAC ACAC ACAC
rs368656359 G/A GG GG GG GG GG GG
rs137990687 G/A GG GG GG GG GG GG
rs201757487 G/- GG GG GG GG GG GG
rs10451132 G/T GG GG GG GG GG GT
rs370702435 A/G AA AA AA AA AA AA
rs121908388 C/T CC CT CT CT CT CT
rs199912760 G/A GG GG GG GG GG GG
rs375106322 G/A GG GG GG GG GG GG
r201860550 G/T GG GG GG GG GG GG
rs149502055 C/T CC CC CC CC CC CC
rs376795685 G/A GG GG GG GG GG GG
rs144013604 A/G AA AA AA AA AA AA
rs75157714 G/A GG GG GG GG GG GG
rs201233994 AT/- AT AT AT AT AT AT
rs200973965 ATAC/- ATAC ATAC ATAC ATAC ATAC ATAC
rs77528321 T/C TT TT TT TT TT TT
rs146702654 T/- TT TT TT TT TT TT
rs6145827 ACACAC/- ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
rs3064638 ACACAC/- ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
ACACAC
- -
rs73584492 A/G AA AA AA AA AA AA
rs190892314 A/G AA AA AA AA AA AA
rs200678983 C/T CC CC CC CC CC CC
rs76797023 A/T AA AA AA AA AA AA
rs77678929 T/A TT TT TT TT TT TT
rs376799359 A/T AA AA AA AA AA AA
rs201103123 C/T CC CC CC CC CC CC
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To determine whether the worldwide recurrent p.R758X
mutation of the CYLD gene is the result of one or more
independent mutational events, we performed haplo-
type analysis. The haplotype analysis of the Spanish,
Dutch and Austrian patients demonstrated that, al-
though the Spanish and the Dutch patients carry the
same haplotype, the clinical appearance, MFT1 and FC,
respectively, is different (Table 1.). These results sug-
gest the importance of modifying genetic and/or envir-
onmental factors. In contrast with these, the Austrian
patient carried a different haplotype than the Spanish
and Dutch families. Thus, we assume the presence of
the same mutation is the consequence of different mu-
tational events (Table 1.).
Conclusion
Our results support the conclusion that position 2272 in
the nucleotide sequence of the CYLD cDNA [NM_015247]
is a mutational hotspot on the CYLD gene. This result
correlates well with our previous findings for Hungarian
and Anglo-Saxon BSS families carrying the same het-
erozygous nonsense mutation (c.2806C > T, p.Arg936X)
but different haplotypes [15]. Of note, both mutational
hotspots are the location of recurrent nonsense mutations.
Regarding the encoded functional domains, both of
mutational hotspots affect the ubiquitin-specific protease
domain of the CYLD protein (Fig. 2c). Both recurrent
nonsense mutations have been reported for all three clin-
ical variants (MFT1, BSS, FC) of the CYLD-mutation
based disease spectrum and have been associated with
high intra- and interfamilial phenotypic diversity [15].
These reports raise the question of how these two
worldwide recurrent nonsense mutations can lead to the
development of the different clinical variants of the
CYLD-mutation based disease spectrum. Further studies
are needed to identify putative genetic, environmental or
lifestyle factors and to elucidate the mechanism leading
to the enormous phenotypic differences observed in pa-
tients carrying the same c.2272C/T, p.R758X nonsense
mutation.
Availability of supporting data
All the supporting data are included as additional file.
Consent to publish
Written informed consent was obtained from all partici-
pants to publish this article.
Fig. 2 Direct sequencing of the CYLD gene. Direct sequencing revealed a nonsense mutation (c.2272C/T, p.R758X) in exon 17. a The affected
family members carried the deletion in heterozygous form. b The unaffected family members carried the wild-type sequence. c The mutation
is located in the region of the ubiquitin-specific protease domain of the CYLD protein
Table 2 Summary of the geographical location and clinical manifestation of the recurrent p.R758X CYLD mutation
CYLD cDNA CYLD protein Detected in patients with Nationality References
c.2272C > T p.R758X FC Caucasian American, Dutch, Japanese [3, 9, 13]
BSS Austrian, South African, Czech, Chinese [10–12]
MFT1 Austrian, Spanish [10, 14], present study
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Additional file
Additional file 1: Sequencing data of Patient III/1 demonstrated the
same heterozygous mutation, which has been detected in case of
Patient II/2. (JPG 163 kb)
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